Filter
93
Filtered Results: 93
Text search:
Comirnaty
Featured
Recommendations
16
New Publications
1
Language
Document type
Guidelines
37
Fact sheets
24
Studies & Reports
12
No document type
5
Manuals
3
Infographics
3
Online Courses
3
Strategic & Response Plan
3
Training Material
1
Brochures
1
Situation Updates
1
Countries / Regions
Germany
12
Argentina
8
Ukraine
7
Brazil
7
Russia
5
Benin
4
China
3
Middle East and North Africa
3
South Africa
3
Central African Republic
3
Mozambique
2
Latin America and the Carribbean
2
Eastern Europe
2
Ecuador
2
Kazakhstan
1
Global
1
Africa
1
Congo, Democratic Republic of
1
Western and Central Europe
1
Paraguay
1
France
1
Tunisia
1
Belarus
1
East and Southern Africa
1
Chad
1
Authors & Publishers
Publication Years
Category
COVID-19
38
Guidelines
11
Information, Education and Communication (IEC)
8
Policies
6
Women & Child Health
5
Studies & Reports
5
Capacity Building
3
Vaccine-preventable Diseases
2
Policies & Guidelines HIV & TB
2
Humanitarian Crisis
2
x MEDBOX Issue Brief & Annual Reports x
1
IEC Material
1
Virology
1
Statistics
1
Pharmacy & Technologies
1
Toolboxes
Country specific documents
21
Biontech/Pfizer Comirnaty
16
Communication Material
14
COVID-19 Vaccination
13
COVID-19 Vaccination Information
13
Immunization Guidelines
9
Access & Strategy
8
Logistics & Supply
8
For Health Worker
5
Anamnesis / Screening
4
For Older People
4
Vector-based Vacines General
4
Information Refugees Ukraine
4
COVID-19
4
Education material
4
Online Courses & Resources
3
For General Public & Community
3
SARS-CoV-2 Variants
3
mRna Vaccines general
3
Booster Doses
3
Country specific
2
Social Worker
2
Infection Control General
2
Diagnostics & Laboratory Guidance
2
For Parents & Children
2
For Migrants & Refugees
2
Long-term Care Facilities
2
Moderna
2
Situation Reports & Updates
2
Refugees & Migrants
2
Volunteers
2
Ebola Prevention & Control
1
Europe
1
Vaccination
1
Pediatrics
1
Child Health / Pediatrics
1
Clinical Guidelines
1
Hand Hygiene
1
Poster & Infographics
1
Training, others
1
For People with Disabilities
1
Paediatrics
1
Vaccination & Strategy
1
Videos
1
Vaccine Candidates & Research
1
Dashboards & Resource Platforms
1
Fair Allocation & Ethical Aspects
1
COVAX Initiative
1
Long COVID/ Post-COVID Syndrome
1
Vaxzevria (Astra Zeneca)
1
Johnson & Johnson
1
Research & Pipeline
1
Inactivated COVID-19 Vaccines
1
Essential Medicines
1
Prices and Patents
1
Reports & Studies
1
Guidelines & Manuals
1
Global Overview
1
Human Rights & the Right to Health
1
Preparedness & Prevention
1
This document aims to provide guidance to healthcare facilities and healthcare providers in the European Union/European Economic Area (EU/EEA) and the United Kingdom (UK) on preparedness and infection prevention and control (IPC) measures for the management of possible and confirmed cases of COVID-1...
COVID-19 & Vaccination
recommended
Issue Brief no.8. January 18,2021
Vaccination against the spread of the SARS-CoV-2 virus represents a milestone in the fight against the pandemic. Good communication and education of the population is essential for the success of the vaccination. Below is some information on vaccination strategies,...
Vacunación frente a la COVID 19: guía de suministro y logística: orientación provisional, 12 febrero de 2021
recommended
12 February 2021
Many critical questions remain about the effectiveness of COVID-19 vaccines in real-world settings. These questions can only be answered in post-introduction vaccine effectiveness studies.This guidance document outlines an approach to leverage existing surveillance systems for Severe Acute Respirato...
This training module is designed to equip HWs with knowledge and communication skills to build their confidence and support them in their ability to promote acceptance of COVID-19 vaccination among other HWs.
interim guidance, 19 July 2021 (arabic version)
updated version: 04/10/2021
Information about vaccine administration
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
A rapid evidence briefing. Vaccinated people are less likely to develop long COVID, even if they get infected, a rapid review of 15 studies by the UK Health Security Agency shows.
COVID-19 Situation Update OPS/WHO Argentina: 10 February 2022
Situation report generated by the OPS/WHO representation in Argentina
8 March 2022
A very large number of people from Ukraine are fleeing the country and entering the European Union (EU) countries bordering Ukraine (Hungary, Poland, Romania, Slovakia) and the EU-neighbourhood country of the Republic of Moldova. Those fleeing Ukraine - mainly women and children - are ...
COVID-19 Progress Report PAHO/WHO Argentina: 24 February 2022
Epidemiología; Resumen de puntos clave de conferencias y declaraciones de interés de OPS/OMS; Variantes de interés y preocupación; Actualización en vacunas; OPS/OMS en redes sociales; Publicaciones relacionadas; Noticias de la Regi...
Covid-19 Epidemiological Surveillance Guide: Public Health Emergency of National Importance for Coronavirus Disease 2019 - version 4
This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals and other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2, ...
Campaña Nacional de Vacunación contra la COVID-19
La dosis de refuerzo está indicada una vez transcurridos los 4 meses (120 días) de la última dosis del esquema inicial y será con vacuna de plataforma ARNm: Pfizer-BioNTech pediátrica a partir de los 5 años o Moderna para uso pediátrico a partir de los 6 años.
La evidencia disponible a nivel internacional sobre el uso de un segundo refuerzo muestra una mayor duración de la respuesta inmune y una disminución de la internación y la mortalidad por COVID 19 en la población de adultos mayores y huéspedes inmunocomprometidos. Por otra parte, el personal de...
